Melanoma epidemiology, biology and prognosis

European Journal of Cancer, Supplement

Volumn 11, Issue 2, 2013, Pages 81-91

  Ali, Z ^a   Yousaf, N ^a   Larkin, J ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN S 100; PROTEIN TYROSINE KINASE; RAF PROTEIN; VASCULOTROPIN;

AMINO ACID SUBSTITUTION; ASIA; AUSTRALIA; CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CELL GROWTH; CELL PROLIFERATION; CELL SURFACE; CELL SURVIVAL; CHROMOSOME 3; CHROMOSOME 6P; CHROMOSOME 9P; CONFERENCE PAPER; CUTANEOUS MELANOMA; DNA DAMAGE; DYSPLASTIC NEVUS; EXON; GENE EXPRESSION PROFILING; GENE LOCUS; GENE MUTATION; GENE SYNTHESIS; GENETIC ASSOCIATION; GENETIC RISK; GENITAL TRACT CANCER; GREECE; HISTOPATHOLOGY; HUMAN; INNATE IMMUNITY; LACTATE DEHYDROGENASE BLOOD LEVEL; LIGAND BINDING; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MALIGNANT TRANSFORMATION; MELANOCYTE; MELANOMA; MITOSIS RATE; MONOSOMY; MUCOSAL MELANOMA; NEW ZEALAND; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; RACE DIFFERENCE; SKIN COLOR; SKIN PIGMENTATION; SKIN TRANSPLANTATION; SKIN ULCER; SKINFOLD THICKNESS; SMOKING; SOMATIC MUTATION; SUN EXPOSURE; SWITZERLAND; SYSTEMATIC REVIEW (TOPIC); TUMOR SUPPRESSOR GENE; ULTRAVIOLET A RADIATION; ULTRAVIOLET RADIATION; UNITED STATES; UVEA MELANOMA; XERODERMA PIGMENTOSUM;

EID: 84884938466     PISSN: 13596349     EISSN: 18781217     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2013.07.012     Document Type: Conference Paper

References (183)

1. Chang A.E., Karnell L.H., Menck H.R. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998, 83:1664-1678.
2. Ferlay J., Shin H.R., Bray F., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
3. Forsea A.M., Del Marmol V., de Vries E., Bailey E.E., Geller A.C. Melanoma incidence and mortality in Europe: new estimates, persistent disparities. Br J Dermatol 2012, 167:1124-1130.
4. Cockburn M., Swetter S.M., Peng D., et al. Melanoma underreporting: why does it happen, how big is the problem, and how do we fix it?. J Am Acad Dermatol 2008, 59:1081-1085.
5. Galvin, A. and Walsh, P. Cancer atlas of the United Kingdom and Ireland 1991-2000 - preliminary pages. Chapter 14 Melanoma of skin. Office of National Statistics; 05 July 2005. SMPS No. 68.
6. Coleman M.P., Esteve J., Damiecki P., Arslan A. Trends in cancer incidence and mortality 1993, International Agency for Research on Cancer.
7. Kohler B.A., Ward E., McCarthy B.J., et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011, 103:714-736.
8. Cancer Statistics. ; 2011 [accessed 17.11.11]. http://info.cancerresearchuk.org/cancerstats/.
9. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
10. Cancer Statistics. ; 2011 [accessed 18.11.11]. http://www.cancerresearchuk.org.
11. Geller J., Swetter S.M., Leyson J., et al. Crafting a melanoma educational campaign to reach middle-aged and older men. J Cutan Med Surg 2006, 10:259-268.
12. Lin J.Y., Fisher D.E. Melanocyte biology and skin pigmentation. Nature 2007, 445:843-850.
13. Rees J.L. Genetics of hair and skin color. Ann Rev Genet 2003, 37:67-90.
14. Bulliard J.L., Cox B., Elwood J.M. Latitude gradients in melanoma incidence and mortality in the non-Maori population of New Zealand. Cancer Cause Control 1994, 5:234-240.
15. Pennello G., Devesa S., Gail M. Association of surface ultraviolet B radiation levels with melanoma and nonmelanoma skin cancer in United States blacks. Cancer Epidemiol Biomarkers Prev 2000, 9:291-297.
16. Lea C.S., Scotto J.A., Buffler P.A., et al. Ambient UVB and melanoma risk in the United States: a case-control analysis. Ann Epidemiol 2007, 17:447-453.
17. Gilchrest B.A., Eller M.S., Geller A.C., Yaar M. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 1999, 340:1341-1348.
18. Garibyan L., Fisher D.E. How sunlight causes melanoma. Curr Oncol Rep 2010, 12:319-326.
19. Elwood J.M., Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer 1997, 73:198-203.
20. Kricker A., Armstrong B.K., Goumas C., et al. Ambient UV, personal sun exposure and risk of multiple primary melanomas. Cancer Cause Control 2007, 18:295-304.
21. Kraemer K.H., Lee M.M., Andrews A.D., Lambert W.C. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. Arch Dermatol 1994, 130:1018-1021.
22. Cooke K.R., Fraser J. Migration and death from malignant melanoma. Int J Cancer 1985, 36:175-178.
23. Holman C.D., Armstrong B.K. Cutaneous malignant melanoma and indicators of total accumulated exposure to the sun: an analysis separating histogenetic types. J Natl Cancer Inst 1984, 73:75-82.
24. Nelemans P.J., Groenendal H., Kiemeney L.A., et al. Effect of intermittent exposure to sunlight on melanoma risk among indoor workers and sun-sensitive individuals. Environ Health Persp 1993, 101:252-255.
25. White E., Kirkpatrick C.S., Lee J.A. Case-control study of malignant melanoma in Washington State. I. Constitutional factors and sun exposure. Am J Epidemiol 1994, 139:857-868.
26. Wang S.Q., Setlow R., Berwick M., et al. Ultraviolet A and melanoma: a review. J Am Acad Dermatol 2001, 44:837-846.
27. Stern R.S. Study PFu. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001, 44:755-761.
28. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: a systematic review. Int J Cancer 2007, 120:1116-1122. International Agency for Research on Cancer Working Group on artificial ultraviolet Light, skin cancer.
29. Lazovich D., Vogel R.I., Berwick M., et al. Indoor tanning and risk of melanoma: a case-control study in a highly exposed population. Cancer Epidemiol Biomarkers Prev 2010, 19:1557-1568.
30. Cust A.E., Armstrong B.K., Goumas C., et al. Sunbed use during adolescence and early adulthood is associated with increased risk of early-onset melanoma. Int J Cancer 2011, 128:2425-2435.
31. Veierod M.B., Adami H.O., Lund E., Armstrong B.K., Weiderpass E. Sun and solarium exposure and melanoma risk: effects of age, pigmentary characteristics, and nevi. Cancer Epidemiol Biomarkers Prev 2010, 19:111-120.
32. El Ghissassi F., Baan R., Straif K., et al. A review of human carcinogens - part D: radiation. Lancet Oncol 2009, 10:751-752.
33. Merimsky O., Inbar M. Cigarette smoking and skin cancer. Clin Dermatol 1998, 16:585-588.
34. Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation 1993, 55:742-747.
35. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996, 61:274-278.
36. Marghoob A.A., Slade J., Salopek T.G., et al. Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma. Screening implications. Cancer 1995, 75:707-714.
37. Kahn H.S., Tatham L.M., Patel A.V., Thun M.J., Heath C.W. Increased cancer mortality following a history of nonmelanoma skin cancer. JAMA 1998, 280:910-912.
38. Rivers J.K. Melanoma. Lancet 1996, 347:803-806.
39. Whiteman D.C., Watt P., Purdie D.M., et al. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003, 95:806-812.
40. Olsen C.M., Zens M.S., Stukel T.A., et al. Nevus density and melanoma risk in women: a pooled analysis to test the divergent pathway hypothesis. Int J Cancer 2009, 124:937-944.
41. DiFronzo L.A., Wanek L.A., Elashoff R., Morton D.L. Increased incidence of second primary melanoma in patients with a previous cutaneous melanoma. Ann Surg Oncol 1999, 6:705-711.
42. Ferrone C.R., Ben Porat L., Panageas K.S., et al. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA 2005, 294:1647-1654.
43. Levi F., Randimbison L., Te V.C., La Vecchia C. High constant incidence rates of second cutaneous melanomas. Int J Cancer 2005, 117:877-879.
44. Fountain J.W., Karayiorgou M., Ernstoff M.S., et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A 1992, 89:10557-10561.
45. Cannon-Albright L.A., Goldgar D.E., Meyer L.J., et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 1992, 258:1148-1152.
46. Hussussian C.J., Struewing J.P., Goldstein A.M., et al. Germline p16 mutations in familial melanoma. Nat Genet 1994, 8:15-21.
47. Kamb A., Gruis N.A., Weaver-Feldhaus J., et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994, 264:436-440.
48. Nobori T., Miura K., Wu D.J., Lois A., Takabayashi K., Carson D.A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994, 368:753-756.
49. Piepkorn M. Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors. J Am Acad Dermatol 2000, 42:705-722. [quiz 23-6].
50. Goldstein A.M., Chan M., Harland M., et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 2007, 44:99-106.
51. Molven A., Grimstvedt M.B., Steine S.J., et al. A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation. Genes Chromosomes Cancer 2005, 44:10-18.
52. Fletcher O., Easton D., Anderson K., Gilham C., Jay M., Peto J. Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst 2004, 96:357-363.
53. Eng C., Li F.P., Abramson D.H., et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993, 85:1121-1128.
54. Chin L., Garraway L.A., Fisher D.E. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006, 20:2149-2182.
55. Berwick M., Orlow I., Hummer A.J., et al. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol Biomarkers Prev 2006, 15:1520-1525.
56. Box N.F., Duffy D.L., Chen W., et al. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 2001, 69:765-773.
57. Demenais F., Mohamdi H., Chaudru V., et al. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. J Natl Cancer Inst 2010, 102:1568-1583.
58. Goldstein A.M., Fraser M.C., Struewing J.P., et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995, 333:970-974.
59. Vasen H.F., Gruis N.A., Frants R.R., et al. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 2000, 87:809-811.
60. Whelan A.J., Bartsch D., Goodfellow P.J. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 1995, 333:975-977.
61. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999;91:1310-6.
62. Kadouri L., Temper M., Grenader T., et al. Absence of founder BRCA1 and BRCA2 mutations in cutaneous malignant melanoma patients of Ashkenazi origin. Fam Cancer 2009, 8:29-32.
63. Bishop D.T., Demenais F., Iles M.M., et al. Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 2009, 41:920-925.
64. Brown K.M., Macgregor S., Montgomery G.W., et al. Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet 2008, 40:838-840.
65. Chatzinasiou F., Lill C.M., Kypreou K., et al. Comprehensive field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma. J Natl Cancer Inst 2011, 103:1227-1235.
66. Weber C.K., Slupsky J.R., Kalmes H.A., Rapp U.R. Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res 2001, 61:3595-3598.
67. Keyse S.M., Dual-specificity M.A.P. Kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev 2008, 27:253-261.
68. Dougherty M.K., Muller J., Ritt D.A., et al. Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell 2005, 17:215-224.
69. Demunter A., Stas M., Degreef H., De Wolf-Peeters C., van den Oord J.J. Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J Invest Dermatol 2001, 117:1483-1489.
70. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
71. Omholt K., Platz A., Kanter L., Ringborg U., Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003, 9:6483-6488.
72. Sharma A., Trivedi N.R., Zimmerman M.A., et al. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 2005, 65:2412-2421.
73. Poynter J.N., Elder J.T., Fullen D.R., et al. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 2006, 16:267-273.
74. Balch C.M., Gershenwald J.E., Soong S.J., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206.
75. Green A.C., Baade P., Coory M., Aitken J.F., Smithers M. Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia. J Clin Oncol 2012, 30:1462-1467.
76. Balch C.M., Soong S.J., Gershenwald J.E., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001, 19:3622-3634.
77. Balch C.M., Wilkerson J.A., Murad T.M., et al. The prognostic significance of ulceration of cutaneous melanoma. Cancer 1980, 45:3012-3017.
78. Schuchter L., Schultz D.J., Synnestvedt M., et al. A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group. Ann Intern Med 1996, 125:369-375.
79. Soong S.J., Shaw H.M., Balch C.M., et al. Predicting survival and recurrence in localized melanoma: a multivariate approach. World J Surg 1992, 16:191-195.
80. Thompson J.F., Soong S.J., Balch C.M., et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol 2011, 29:2199-2205.
81. Nagore E., Oliver V., Botella-Estrada R., et al. Prognostic factors in localized invasive cutaneous melanoma: high value of mitotic rate, vascular invasion and microscopic satellitosis. Melanoma Res 2005, 15:169-177.
82. Kashani-Sabet M., Sagebiel R.W., Ferreira C.M., Nosrati M., Miller J.R. Vascular involvement in the prognosis of primary cutaneous melanoma. Arch Dermatol 2001, 137:1169-1173.
83. Kashani-Sabet M., Sagebiel R.W., Ferreira C.M., Nosrati M., Miller J.R. Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. J Clin Oncol 2002, 20:1826-1831.
84. Xu X., Chen L., Guerry D., et al. Lymphatic invasion is independently prognostic of metastasis in primary cutaneous melanoma. Clin Cancer Res 2012, 18:229-237.
85. Callender G.G., Egger M.E., Burton A.L., et al. Prognostic implications of anatomic location of primary cutaneous melanoma of 1mm or thicker. Am J Surg 2011, 202:659-664. [discussion 64-5].
86. Garbe C., Buttner P., Bertz J., et al. Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 1995, 75:2484-2491.
87. Balch C.M., Gershenwald J.E., Soong S.J., et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010, 28:2452-2459.
88. Day C.L., Harrist T.J., Gorstein F., et al. Malignant melanoma. Prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat. Ann Surg 1981, 194:108-112.
89. Chang C.K., Jacobs I.A., Vizgirda V.M., Salti G.I. Melanoma in the elderly patient. Arch Surg 2003, 138:1135-1138.
90. Austin P.F., Cruse C.W., Lyman G., et al. Age as a prognostic factor in the malignant melanoma population. Ann Surg Oncol 1994, 1:487-494.
91. Masback A., Olsson H., Westerdahl J., Ingvar C., Jonsson N. Prognostic factors in invasive cutaneous malignant melanoma: a population-based study and review. Melanoma Res 2001, 11:435-445.
92. Vossaert K.A., Silverman M.K., Kopf A.W., et al. Influence of gender on survival in patients with stage I malignant melanoma. J Am Acad Dermatol 1992, 26:429-440.
93. Joosse A., Collette S., Suciu S., et al. Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials. J Clin Oncol 2012, 30:2240-2247.
94. Shivers S.C., Wang X., Li W., et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 1998, 280:1410-1415.
95. Martenson E.D., Hansson L.O., Nilsson B., et al. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol 2001, 19:824-831.
96. Tarhini A.A., Stuckert J., Lee S., Sander C., Kirkwood J.M. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol 2009, 27:38-44.
97. Long G.V., Menzies A.M., Nagrial A.M., et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011, 29:1239-1246.
98. Moreau S., Saiag P., Aegerter P., et al. Prognostic value of BRAF(V(6)(0)(0)) mutations in melanoma patients after resection of metastatic lymph nodes. Ann Surg Oncol 2012, 19:4314-4321.
99. Safaee Ardekani G., Jarafnejad S., Tan L., Saeedi A., Li G. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One 2012, 7:e47054.
100. Virgili G., Gatta G., Ciccolallo L., et al. Incidence of uveal melanoma in Europe. Ophthalmology 2007, 114:2309-2315.
101. Kujala E., Makitie T., Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophth Vis Sci 2003, 44:4651-4659.
102. Mortality in patients with small choroidal melanoma. COMS Report No. 4. The Collaborative Ocular Melanoma Study Group. Arch Ophthalmol 1997;115:886-93.
103. Singh A.D., Turell M.E., Topham A.K. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 2011, 118:1881-1885.
104. Miller B., Abrahams C., Cole G.C., Proctor N.S. Ocular malignant melanoma in South African blacks. Br J Ophthalmol 1981, 65:720-722.
105. Kuo P.K., Puliafito C.A., Wang K.M., Liu H.S., Wu B.F. Uveal melanoma in China. Int Ophthalmol Clin 1982, 22:57-71.
106. Seddon J.M., Gragoudas E.S., Glynn R.J., et al. Host factors, UV radiation, and risk of uveal melanoma. A case-control study. Arch Ophthalmol 1990, 108:1274-1280.
107. Holly E.A., Aston D.A., Char D.H., Kristiansen J.J., Ahn D.K. Uveal melanoma in relation to ultraviolet light exposure and host factors. Cancer Res 1990, 50:5773-5777.
108. Rootman J., Gallagher R.P. Color as a risk factor in iris melanoma. Am J Ophthalmol 1984, 98:558-561.
109. Tucker M.A., Shields J.A., Hartge P., et al. Sunlight exposure as risk factor for intraocular malignant melanoma. N Eng J Med 1985, 313:789-792.
110. Vajdic C.M., Kricker A., Giblin M., et al. Sun exposure predicts risk of ocular melanoma in Australia. Int J Cancer 2002, 101:175-182.
111. Gallagher R.P., Elwood J.M., Rootman J., et al. Risk factors for ocular melanoma: Western Canada Melanoma Study. J Natl Cancer Inst 1985, 74:775-778.
112. Pane A.R., Hirst L.W. Ultraviolet light exposure as a risk factor for ocular melanoma in Queensland, Australia. Ophth Epidem 2000, 7:159-167.
113. Brantley M.A., Harbour J.W. Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region. Cancer Res 2000, 60:4320-4323.
114. Loercher A.E., Tank E.M., Delston R.B., Harbour J.W. MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J Cell Biol 2005, 168:35-40.
115. Brantley M.A., Harbour J.W. Deregulation of the Rb and p53 pathways in uveal melanoma. Am J Pathol 2000, 157:1795-1801.
116. Abdel-Rahman M.H., Yang Y., Zhou X.P., et al. High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma. J Clin Oncol 2006, 24:288-295.
117. Neves S.R., Ram P.T., Iyengar R. G protein pathways. Science 2002, 296:1636-1639.
118. Van Raamsdonk C.D., Bezrookove V., Green G., et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009, 457:599-602.
119. Onken M.D., Worley L.A., Long M.D., et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Inv Ophth Vis Sci 2008, 49:5230-5234.
120. Van Raamsdonk C.D., Griewank K.G., Crosby M.B., et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010, 363:2191-2199.
121. Lee D.H., Pfeifer G.P. Deamination of 5-methylcytosines within cyclobutane pyrimidine dimers is an important component of UVB mutagenesis. J Biol Chem 2003, 278:10314-10321.
122. Wu X., Li J., Zhu M., Fletcher J.A., Hodi F.S. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-kappaB pathways. Mol Cancer Ther 2012, 11:1905-1914.
123. Khalili J.S., Yu X., Wang J., et al. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res 2012, 18:4345-4355.
124. Harbour J.W., Onken M.D., Roberson E.D., et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010, 330:1410-1413.
125. Jensen D.E., Proctor M., Marquis S.T., et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998, 16:1097-1112.
126. Machida Y.J., Machida Y., Vashisht A.A., Wohlschlegel J.A., Dutta A. The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. J Biol Chem 2009, 284:34179-34188.
127. Nishikawa H., Wu W., Koike A., et al. BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity. Cancer Res 2009, 69:111-119.
128. Carbone M., Ferris L.K., Baumann F., et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med 2012, 10:179.
129. Njauw C.N., Kim I., Piris A., et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One 2012, 7:e35295.
130. Wiesner T., Obenauf A.C., Murali R., et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011, 43:1018-1021.
131. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359:843-845.
132. Boyd S.R., Tan D., Bunce C., et al. Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. Br J Oph 2002, 86:448-452.
133. Missotten G.S., Notting I.C., Schlingemann R.O., et al. Vascular endothelial growth factor a in eyes with uveal melanoma. Arch Ophth 2006, 124:1428-1434.
134. el Filali M., Missotten G.S., Maat W., et al. Regulation of VEGF-A in uveal melanoma. Inv Ophth Vis Sci 2010, 51:2329-2337.
135. Sheidow T.G., Hooper P.L., Crukley C., Young J., Heathcote J.G. Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis. Br J Ophth 2000, 84:750-756.
136. Horsman D.E., White V.A. Cytogenetic analysis of uveal melanoma. Consistent occurrence of monosomy 3 and trisomy 8q. Cancer 1993, 71:811-819.
137. Horsman D.E., Sroka H., Rootman J., White V.A. Monosomy 3 and isochromosome 8q in a uveal melanoma. Cancer Genet Cytogen 1990, 45:249-253.
138. Augsburger J.J., Gamel J.W. Clinical prognostic factors in patients with posterior uveal malignant melanoma. Cancer 1990, 66:1596-1600.
139. Seddon J.M., Polivogianis L., Hsieh C.C., et al. Death from uveal melanoma. Number of epithelioid cells and inverse SD of nucleolar area as prognostic factors. Arch Ophth 1987, 105:801-806.
140. Prescher G., Bornfeld N., Hirche H., et al. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996, 347:1222-1225.
141. Shields C.L., Ganguly A., Bianciotto C.G., et al. Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens. Ophthalmology 2011, 118:396-401.
142. Prescher G., Bornfeld N., Friedrichs W., Seeber S., Becher R. Cytogenetics of twelve cases of uveal melanoma and patterns of nonrandom anomalies and isochromosome formation. Cancer Genet Cytogen 1995, 80:40-46.
143. White V.A., Chambers J.D., Courtright P.D., Chang W.Y., Horsman D.E. Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer 1998, 83:354-359.
144. Sisley K., Parsons M.A., Garnham J., et al. Association of specific chromosome alterations with tumour phenotype in posterior uveal melanoma. Br J Cancer 2000, 82:330-338.
145. Onken M.D., Worley L.A., Ehlers J.P., Harbour J.W. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004, 64:7205-7209.
146. Lu Y., Zhu W.Y., Tan C., Yu G.H., Gu J.X. Melanocytes are potential immunocompetent cells: evidence from recognition of immunological characteristics of cultured human melanocytes. Pigment cell Res 2002, 15:454-460.
147. Le Poole I.C., Mutis T., van den Wijngaard R.M., et al. A novel, antigen-presenting function of melanocytes and its possible relationship to hypopigmentary disorders. J Immunol 1993, 151:7284-7292.
148. Mackintosh J.A. The antimicrobial properties of melanocytes, melanosomes and melanin and the evolution of black skin. J Theor Biol 2001, 211:101-113.
149. Plonka P.M., Passeron T., Brenner M., et al. What are melanocytes really doing all day long...?. Exp Dermatol 2009, 18:799-819.
150. McLaughlin C.C., Wu X.C., Jemal A., Martin H.J., Roche L.M., Chen V.W. Incidence of noncutaneous melanomas in the US. Cancer 2005, 103:1000-1007.
151. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
152. Mallone S., De Vries E., Guzzo M., et al. Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe. Eur J Cancer 2012, 48:1167-1175.
153. Patrick R.J., Fenske N.A., Messina J.L. Primary mucosal melanoma. J Am Acad Dermatol 2007, 56:828-834.
154. Sutherland C.M., Chmiel J.S., Henson D.E., Winchester D.P. Patient characteristics, methods of diagnosis, and treatment of mucous membrane melanoma in the United States of America. J Am Coll Surg 1994, 179:561-566.
155. Pandey M., Mathew A., Abraham E.K., Ahamed I.M., Nair K.M. Primary malignant melanoma of the mucous membranes. Eur J Surg Oncol 1998, 24:303-307.
156. Pandey M., Mathew A., Iype E.M., et al. Primary malignant mucosal melanoma of the head and neck region: pooled analysis of 60 published cases from India and review of literature. Eur J Cancer Prev 2002, 11:3-10.
157. Hicks M.J., Flaitz C.M. Oral mucosal melanoma: epidemiology and pathobiology. Oral Oncol 2000, 36:152-169.
158. Dahlgren L., Schedvins K., Kanter-Lewensohn L., Dalianis T., Ragnarsson-Olding B.K. Human papilloma virus (HPV) is rarely detected in malignant melanomas of sun sheltered mucosal membranes. Acta Oncol 2005, 44:694-699.
159. Lundberg R., Brytting M., Dahlgren L., et al. Human herpes virus DNA is rarely detected in non-UV light-associated primary malignant melanomas of mucous membranes. Anticancer Res 2006, 26:3627-3631.
160. Cote T.R., Sobin L.H. Primary melanomas of the esophagus and anorectum: epidemiologic comparison with melanoma of the skin. Melanoma Res 2009, 19:58-60.
161. Burgi A., Brodine S., Wegner S., et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 2005, 104:1505-1511.
162. Holmstrom M., Lund V.J. Malignant melanomas of the nasal cavity after occupational exposure to formaldehyde. Br J Ind Med 1991, 48:9-11.
163. Axell T., Hedin C.A. Epidemiologic study of excessive oral melanin pigmentation with special reference to the influence of tobacco habits. Scand J Dent Res 1982, 90:434-442.
164. Manolidis S., Donald P.J. Malignant mucosal melanoma of the head and neck: review of the literature and report of 14 patients. Cancer 1997, 80:1373-1386.
165. Takagi M., Ishikawa G., Mori W. Primary malignant melanoma of the oral cavity in Japan. With special reference to mucosal melanosis. Cancer 1974, 34:358-370.
166. Maldonado J.L., Fridlyand J., Patel H., et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 2003, 95:1878-1890.
167. Curtin J.A., Fridlyand J., Kageshita T., et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005, 353:2135-2147.
168. Grabbe J., Welker P., Dippel E., Czarnetzki B.M. Stem cell factor, a novel cutaneous growth factor for mast cells and melanocytes. Arch Derm Res 1994, 287:78-84.
169. Lev S., Yarden Y., Givol D. Dimerization and activation of the kit receptor by monovalent and bivalent binding of the stem cell factor. J Biol Chem 1992, 267:15970-15977.
170. Giebel L.B., Spritz R.A. Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism. Proc Natl Acad Sci U S A 1991, 88:8696-8699.
171. Nishikawa S., Kusakabe M., Yoshinaga K., et al. In utero manipulation of coat color formation by a monoclonal anti-c-kit antibody: two distinct waves of c-kit-dependency during melanocyte development. EMBO J 1991, 10:2111-2118.
172. Wehrle-Haller B., Weston J.A. Soluble and cell-bound forms of steel factor activity play distinct roles in melanocyte precursor dispersal and survival on the lateral neural crest migration pathway. Development 1995, 121:731-742.
173. Alexeev V., Yoon K. Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J Invest Dermatol 2006, 126:1102-1110.
174. Natali P.G., Nicotra M.R., Winkler A.B., Cavaliere R., Bigotti A., Ullrich A. Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer 1992, 52:197-201.
175. Montone K.T., van Belle P., Elenitsas R., Elder D.E. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol 1997, 10:939-944.
176. Bastian B.C., LeBoit P.E., Hamm H., Brocker E.B., Pinkel D. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 1998, 58:2170-2175.
177. Bastian B.C., Kashani-Sabet M., Hamm H., et al. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res 2000, 60:1968-1973.
178. van Dijk M., Sprenger S., Rombout P., et al. Distinct chromosomal aberrations in sinonasal mucosal melanoma as detected by comparative genomic hybridization. Genes Chromosomes Canc 2003, 36:151-158.
179. Curtin J.A., Busam K., Pinkel D., Bastian B.C. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006, 24:4340-4346.
180. Beadling C., Jacobson-Dunlop E., Hodi F.S., et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008, 14:6821-6828.
181. Rivera R.S., Nagatsuka H., Gunduz M., et al. C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch 2008, 452:27-32.
182. Monsel G., Ortonne N., Bagot M., Bensussan A., Dumaz N. C-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytes. Oncogene 2010, 29:227-236.
183. Kong Y., Si L., Zhu Y., et al. Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 2011, 17:1684-1691.